These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
498 related articles for article (PubMed ID: 19116269)
1. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Dubrovska A; Kim S; Salamone RJ; Walker JR; Maira SM; García-Echeverría C; Schultz PG; Reddy VA Proc Natl Acad Sci U S A; 2009 Jan; 106(1):268-73. PubMed ID: 19116269 [TBL] [Abstract][Full Text] [Related]
2. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Dubrovska A; Elliott J; Salamone RJ; Kim S; Aimone LJ; Walker JR; Watson J; Sauveur-Michel M; Garcia-Echeverria C; Cho CY; Reddy VA; Schultz PG Clin Cancer Res; 2010 Dec; 16(23):5692-702. PubMed ID: 21138868 [TBL] [Abstract][Full Text] [Related]
3. PTEN loss-mediated Akt activation increases the properties of cancer stem-like cell populations in prostate cancer. Kim RJ; Bae E; Hong YK; Hong JY; Kim NK; Ahn HJ; Oh JJ; Park DS Oncology; 2014; 87(5):270-9. PubMed ID: 25139413 [TBL] [Abstract][Full Text] [Related]
4. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921 [TBL] [Abstract][Full Text] [Related]
5. EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop. Yang CF; Yang GD; Huang TJ; Li R; Chu QQ; Xu L; Wang MS; Cai MD; Zhong L; Wei HJ; Huang HB; Huang JL; Qian CN; Huang BJ Oncogene; 2016 Jun; 35(26):3419-31. PubMed ID: 26568302 [TBL] [Abstract][Full Text] [Related]
6. Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. Rybak AP; He L; Kapoor A; Cutz JC; Tang D Biochim Biophys Acta; 2011 May; 1813(5):683-94. PubMed ID: 21277911 [TBL] [Abstract][Full Text] [Related]
7. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype. Hong SW; Shin JS; Moon JH; Kim YS; Lee J; Choi EK; Ha SH; Lee DH; Chung HN; Kim JE; Kim KP; Hong YS; Lee JL; Lee WJ; Choi EK; Lee JS; Jin DH; Kim TW Apoptosis; 2014 May; 19(5):895-904. PubMed ID: 24652480 [TBL] [Abstract][Full Text] [Related]
8. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation. Al-Dhfyan A; Alhoshani A; Korashy HM Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884 [TBL] [Abstract][Full Text] [Related]
9. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells. Axanova LS; Chen YQ; McCoy T; Sui G; Cramer SD Prostate; 2010 Nov; 70(15):1658-71. PubMed ID: 20583132 [TBL] [Abstract][Full Text] [Related]
10. [Metformin induces apoptosis in hepatocellular carcinoma Huh-7 cells in vitro and its mechanism]. Lin F; Yan W; Wen T; Wu GY Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):742-6. PubMed ID: 24378094 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway. Wang F; Li L; Chen Z; Zhu M; Gu Y Int J Mol Med; 2016 May; 37(5):1421-8. PubMed ID: 26951965 [TBL] [Abstract][Full Text] [Related]
12. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis. Tan M; Xu J; Siddiqui J; Feng F; Sun Y Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21 pathway. Chang YL; Zhou PJ; Wei L; Li W; Ji Z; Fang YX; Gao WQ Oncotarget; 2015 Sep; 6(27):24017-31. PubMed ID: 26172296 [TBL] [Abstract][Full Text] [Related]
14. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453 [TBL] [Abstract][Full Text] [Related]
15. PTEN-deficient cancers depend on PIK3CB. Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892 [TBL] [Abstract][Full Text] [Related]
16. PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells. Chen J; Shao R; Li F; Monteiro M; Liu JP; Xu ZP; Gu W Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1317-26. PubMed ID: 26399781 [TBL] [Abstract][Full Text] [Related]
17. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Fang J; Ding M; Yang L; Liu LZ; Jiang BH Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033 [TBL] [Abstract][Full Text] [Related]
18. THBS4 silencing regulates the cancer stem cell-like properties in prostate cancer via blocking the PI3K/Akt pathway. Hou Y; Li H; Huo W Prostate; 2020 Jul; 80(10):753-763. PubMed ID: 32421868 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN. Zhou K; Zhang T; Fan Y; Serick ; Du G; Wu P; Geng D Tumour Biol; 2016 Oct; 37(10):13469-13477. PubMed ID: 27465551 [TBL] [Abstract][Full Text] [Related]
20. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway. He K; Xu T; Xu Y; Ring A; Kahn M; Goldkorn A Int J Cancer; 2014 Jan; 134(1):43-54. PubMed ID: 23784558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]